Through the inhibition of the CTLA4 via ipilimumab and the application of adoptive cellular immunotherapy with tumor-infiltrated lymphocytes, it enhanced the anti-tumor effects of T cells (Besser et al., 2010; Hodi et al., 2010). The gene discussed is CTLA4; the disease is neoplasm.